Faculty profile

Marc-André Langlois

Back to faculty

Associate ProfessorBiochemistry, Microbiology and ImmunologyUniversity of Ottawa

Marc-André Langlois

Associate Professor

Biochemistry, Microbiology and Immunology

Faculty of Medicine

University of Ottawa

Ottawa, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
7 publications in the last five years, latest in 2026.
Principal investigator on 20 research grants (17 CIHR, 2 NSERC, 1 SSHRC), most recently in 2025.
Supervisor on 1 trainee award (1 CIHR), most recently in 2021.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile Personal Website Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Ottawa profile.

Covid-19 Sars-Cov-2 Antibodies Molecular Virology Cellular Immunity Serology Viral Load Testing Virus Neutralization

Latest papers

Three Doses and Six Months Later: Real-World SARS-CoV-2 Specific Humoral and Cell-Mediated Immunity in Children With Inborn Errors of Immunity.
Journal of clinical immunology · 2026
Incremental immunogenicity of multiple doses of SARS‐CoV‐2 vaccination in patients with haematological malignancies
British Journal of Haematology · 2025
COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies
Vaccine · 2024

All 7 publications

Latest funding

Empowering Large-Scale Infectious Disease Research and Mobilizing Knowledge: The Serology and Diagnostics High-Throughput Platform as Critical Research Infrastructure for Pandemic Preparedness, Surveillance, and Response in Canada
CIHR · 2025 · Nominated PI
$2,999,998
Molecular and Antibody Surveillance of H5N1 in Animals and Humans using a High Throughput Diagnostic Platform
CIHR · 2024 · Nominated PI
$150,000
The COVID-R3ICSAB Study: COVID-19 Wide Impact: Research on the Risk and Resilience In Special Communities of Chinese, South Asian and Black Populations
CIHR · 2021 · Co-investigator
$498,210

All 23 grants and awards

7 publications.

Three Doses and Six Months Later: Real-World SARS-CoV-2 Specific Humoral and Cell-Mediated Immunity in Children With Inborn Errors of Immunity.

Porto LLTN, Yazji D, Unninayar D, Decaluwe H, Derfalvi B, Palma A, Issekutz T, Kalashnikova T, Murguía-Favela L, Pham-Huy A, Rubin T, Suresh S, Upton J, Wright NAM, Chapdelaine H, Falcone EL, Top KA, Sadarangani M, Vinh DC, Barrett L, Oldford S, Langlois MA, Arnold C, Zhang T, Ramsay T, Cowan J, VISID study investigators

Journal of clinical immunology2026

DOI: 10.1007/s10875-026-02021-1 PMID: 42034835

Incremental immunogenicity of multiple doses of SARS‐CoV‐2 vaccination in patients with haematological malignancies

Vijenthira A, Bhella S, Hueniken K, Wilkin AM, Sebag M, Wang P, Hicks LK, Hay AE, Assouline S, Balitsky A

British Journal of Haematology2025

DOI: 10.1111/bjh.70054

COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies

Bhella S, Wilkin AM, Hueniken K, Vijenthira A, Sebag M, Wang P, Hicks LK, Hay AE, Assouline S, Fraser G

Vaccine20247 citations

DOI: 10.1016/j.vaccine.2024.06.041

Humoral and cell-mediated immune responses to COVID-19 vaccines up to 6 months post three-dose primary series in adults with inborn errors of immunity and their breakthrough infections.

Unninayar D, Falcone EL, Chapdelaine H, Vinh DC, Top KA, Derfalvi B, Issekutz TB, Decaluwe H, Pham-Huy A, Upton J, Betschel SD, Rubin T, Suresh S, Wright NAM, Murguía-Favela L, Kalashnikova T, Barrett L, Oldford S, Langlois MA, Arnold C, Sadarangani M, Zhang T, Ramsay T, Yazji D, Cowan J

Frontiers in immunology2024

DOI: 10.3389/fimmu.2024.1501908 PMID: 39906736

Booster doses of COVID-19 vaccine enhance neutralization efficiency against XBB.1.5.

Sakr E, Almeida ND, Langlois MA, Dasgupta K, Mazer BD

The Journal of allergy and clinical immunology2024

DOI: 10.1016/j.jaci.2023.11.912 PMID: 38159096

The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study.

Almeida ND, Schiller I, Ke D, Sakr E, Plesa M, Vanamala S, Moneger AL, Bazan M, Lucchesi C, Wozniak N, Fritz JH, Piccirillo CA, Pelchat M, Arnold C, Galipeau Y, McCluskie PS, Langlois MA, Dasgupta K, Mazer BD

Frontiers in immunology2024

DOI: 10.3389/fimmu.2024.1330549 PMID: 38433831

Results of the Stop the Spread Ottawa (SSO) cohort study: a Canadian urban-based prospective evaluation of antibody responses and neutralisation efficiency to SARS-CoV-2 infection and vaccination.

Keeshan A, Galipeau Y, Heiskanen A, Collins E, McCluskie PS, Arnold C, Saginur R, Booth R, Little J, McGuinty M, Buchan CA, Crawley A, Langlois MA, Cooper C

BMJ open2023

DOI: 10.1136/bmjopen-2023-077714 PMID: 37907304

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2025

Subject: Prospective PhD student: Covid-19 Dear Professor Langlois, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Three Doses and Six Months Later: Real-World SARS-CoV-2 Specific Humoral and Cell-Mediated Immunity in Children With Inborn Errors of Immunity." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Empowering Large-Scale Infectious Disease Research and Mobilizing Knowledge: The Serology and Diagnostics High-Throughput Platform as Critical Research Infrastructure for Pandemic Preparedness, Surveillance, and Response in Canada" (2025), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Marc-André Langlois

Research

Latest papers

Latest funding

Three Doses and Six Months Later: Real-World SARS-CoV-2 Specific Humoral and Cell-Mediated Immunity in Children With Inborn Errors of Immunity.

Incremental immunogenicity of multiple doses of SARS‐CoV‐2 vaccination in patients with haematological malignancies

COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies

Humoral and cell-mediated immune responses to COVID-19 vaccines up to 6 months post three-dose primary series in adults with inborn errors of immunity and their breakthrough infections.

Booster doses of COVID-19 vaccine enhance neutralization efficiency against XBB.1.5.

The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study.

Results of the Stop the Spread Ottawa (SSO) cohort study: a Canadian urban-based prospective evaluation of antibody responses and neutralisation efficiency to SARS-CoV-2 infection and vaccination.

Empowering Large-Scale Infectious Disease Research and Mobilizing Knowledge: The Serology and Diagnostics High-Throughput Platform as Critical Research Infrastructure for Pandemic Preparedness, Surveillance, and Response in Canada

Molecular and Antibody Surveillance of H5N1 in Animals and Humans using a High Throughput Diagnostic Platform

The COVID-R3ICSAB Study: COVID-19 Wide Impact: Research on the Risk and Resilience In Special Communities of Chinese, South Asian and Black Populations

Pregnant and Lactating Individuals & Newborns COVID-19 Vaccination Study

Vaccine effectiveness against SARS-CoV-2 variants of concern in long-term care populations: a multi-province study

Coronavirus Variants Rapid Response Network: CoVaRR-Net

COVID-19 Variant Supplement - Analysis of Antibody Neutralization Efficiency and Cellular Immunity in SARS-CoV-2-Positive Individuals Identified in At-Risk Individuals

Longitudinal Cohort Analysis of Antibody Responses Neutralization Efficiency and Long-Term Immunity in natural SARS-CoV-2 infection, Vaccination and its robustness against emerging Variants of Concern.

Coronavirus Variants Rapid Response Network: CoVaRR-Net - Extension

A living evidence approach to variants of concern (VOC) and COVID-19 vaccine effectiveness

Frequent collaborators

Curtis Cooper

Juthaporn Cowan

Manish Sadarangani

Beata Derfalvi

Kaberi Dasgupta

Amaris Karin Balitsky

Michael Sebag

Raphael Saginur

Julian Little

Ronald Booth

Kaberi Dasgupta

Michaeline McGuinty

Martin Pelchat

Angela Crawley

Thomas Issekutz